Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: CON, TRI

Huma collaborates with Bayer to advance precision treatment for lung cancer

LONDON and NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Healthtech company Huma and the life sciences company Bayer will use machine learning to try to improve diagnosis for certain types of lung cancer, by more precise readings of CT (Computed Tomography) scans.

Huma Logo

The companies aim to distinguish different forms of non-small-cell lung carcinomas (NSCLCs) from CT scans. This would enable specialists to more rapidly determine which form of cancer a patient has, in order to begin more appropriate, timely treatment.

In the age of precision medicine, patients will undergo a series of tests to characterize their cancer. However, these tests can be invasive and often drive up time to results, hence treatment, and costs. In order to move beyond a "one-size-fits-all" treatment approach and ensure the right patients are being treated at the right time with the right medication, there's an urgent need for new ways to understand each patient's cancer. Experts have begun using machine learning to help categorise and segment patient subtypes with some diseases and Huma and Bayer are turning the technology to NSCLCs.

The research project will begin by using machine learning to spot correlations in molecular and imaging assessments such as "ground glass opacity" that can differentiate lung cancer types. The team will then create, train and test models that can accurately diagnose the different types of lung cancers.

Dan Vahdat, CEO and Founder of Huma, said: "We have shown we can use machine learning to predict an individual's risk of depression, anxiety, cardiac events and the impact of being infected by COVID-19, and we hope this work in cancer will be a new field for us. However, as always, we will publish any significant developments in peer-reviewed journals. We know the importance of evidence-based, rigorous innovation and, by doing it the right way, we can more rapidly make meaningful, impactful changes and help people live longer, fuller lives.

"We want to start by providing more personalised care for people with non-small cell lung cancer. In the future, our vision is to include other cancers and even other therapeutic areas such as rare diseases. We want to broaden our existing smartphone platform to combine imaging, digital phenotyping, and genomics with the real-world, real-time data from patients that we already collect. We want to take therapies from bench to bedside to breakfast table."

Robert LaCaze, Head of Oncology, Pharmaceuticals Division of Bayer, added: "Rather than treating all lung cancer patients with standardized regimens, precision medicine can allow physicians to prescribe medicines tailored to the tumor's specific oncogenic driver. Our collaboration leverages Huma's proven expertise in Machine Learning and Bayer's vast capabilities in Oncology and Medical Imaging to help accelerate the identification of those patients with certain types of non-small cell lung cancer who can most benefit from these tailored treatments."

Leaps by Bayer, the impact investment arm of Bayer, has been a Series B (2019) and Series C (2021) investor into Huma. Huma and Bayer plan to begin work on this project immediately.

About Huma
Huma is a global health technology company that exists to help people live longer, fuller lives. Our modular platform supports better care as a digital 'hospital at home' for a range of use cases across different disease areas and better research by powering some of the world's largest decentralized clinical trials and studies in life sciences. We use digital biomarkers, predictive algorithms and real-world data from continuous patient monitoring to advance proactive, predictive care. 

Our 'hospitals at home' help care for patients across England's NHS, Wales, Germany, and the UAE ? evidence shows they can double clinical capacity, reduce readmission rates by a third, and reduce costs whilst providing safe, high-quality care. We offer Covid-19 digital services, not-for-profit, to national governments in support of the fight against the pandemic and have shipped over a million devices that complement our 'hospitals at home' to help power them. We are using the same technology platform to support decentralized clinical trials. www.huma.com

Logo - https://mma.prnewswire.com/media/1427908/Huma_Logo.jpg

These press releases may also interest you

at 11:47
Intentional Disruption: Leadership Lessons in Healthcare, Business and Beyond by former Kindred Healthcare CEO, Benjamin Breier is now available....

at 11:45
IR-Med ("IR-Med or the "Company") is pleased to announce that IR-Med has been approved by OTC Markets to up-list from Pink Sheet to the OTCQB tier after IR-Med satisfied the required uplist criteria. Effective as of February 1st, 2022, IR-Med will...

at 11:40
symplr, the leader in enterprise healthcare operations including governance, risk management, and compliance ("GRC") software-as-a-service ("SaaS ") solutions, today announced its golf sponsorship program with four top-ranked professional golfers....

at 11:30
The "Chimeric Antigen Receptor (CAR) T-Cell Therapy - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor (CAR) T-Cell Therapy epidemiology division provides insights about...

at 11:30
The "Allogenic iNKT cell therapy - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Allogenic iNKT cell therapy epidemiology division provides insights about historical and current patient pool and...

at 11:30
The French authorities validate the start of the therapeutic trial to evaluate the safety of the ExOlin® device for patients suffering from poorly controlled type 1 diabetes with severe glycaemic fluctuations and prone to severe hypoglycaemia....

News published on 29 september 2021 at 04:03 and distributed by: